Mind Medicine Stock Price, News & Analysis

Mind Medicine (MindMed) has announced a new program to develop R(-)-MDMA aimed at treating social anxiety and improving functioning for conditions like Autism Spectrum Disorder (ASD). This initiative represents a significant expansion of MindMed's drug pipeline, addressing a substantial unmet medical need, particularly as ASD affects around 2% of the U.S. population. With no approved therapies targeting core ASD symptoms, the estimated economic cost of ASD in the U.S. is projected to reach $461 billion by 2025. Initial clinical trials for R(-)-MDMA are expected to begin in 2022.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced that Chief Medical Officer Daniel R. Karlin will chair The Digital Biomarkers & Digital Measurements Summit on October 26-27, 2021. Dr. Karlin emphasized the importance of bridging the gap between technological promises and real-world applications in healthcare. The summit aims to enhance understanding and collaboration in the realm of digital biomarkers and measurements, which are critical in pharmaceutical development. MindMed focuses on developing psychedelic-inspired therapies targeting addiction and mental health disorders.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has joined the Clinical Trials Transformation Initiative (CTTI) to enhance the quality and efficiency of clinical trials. As one of about 80 member organizations, MindMed aims to drive innovations in clinical research. The company, represented by its Chief Medical Officer, emphasizes its commitment to improving the clinical trial process and ensuring the accessibility of psychedelic therapies in mental healthcare. CTTI's vision, 'Transforming Trials 2030', focuses on patient-centered, quality trials integrated into health processes.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has partnered with Sphere Health to advance mental health research, specifically targeting anxiety and affective disorders. The collaboration seeks to utilize consumer technology to gather multimodal data for a new study, MM061302. This initiative aims to enhance machine learning tools for predicting symptoms of mental health conditions. The study will maintain patient privacy through de-identified data linked with Datavant. MindMed emphasizes the need for more research to improve treatment methodologies while ensuring ethical standards in clinical care.

Mind Medicine (MindMed) has appointed Andreas Krebs and Carol Vallone as directors, effective immediately. Krebs, an experienced executive and author, has a background in growth companies and leadership roles at major corporations. Vallone is known for her track record in launching and scaling companies and has held key positions in healthcare and education sectors. The appointments follow the departure of Bruce Linton, who contributed to the company's growth. Their addition aims to enhance MindMed's strategic direction in developing psychedelic-inspired therapies. Regulatory approval is pending.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has appointed Dr. Bryan L. Roth to its Scientific Advisory Board. Dr. Roth, a leading researcher in molecular neuropharmacology with over 30 years of experience, aims to develop psychedelics without hallucinogenic effects. He has secured a $27 million grant from the Defense Advanced Research Projects Agency to support the Ultra Large-Scale-Docking program, which identifies compounds that activate serotonin receptors without causing hallucinations. MindMed's CEO expressed confidence in Dr. Roth's expertise to enhance the company's research and development efforts.

MindMed (NASDAQ: MNMD) announces CEO Robert Barrow will speak at the Benzinga Healthcare Small Cap Conference on September 29-30, 2021. Barrow's interview is scheduled for 11:30am ET on September 30, with a replay available on MindMed's website for 30 days. MindMed focuses on developing psychedelic-inspired therapies aimed at addressing addiction and mental health issues, with a diverse pipeline including substances like psilocybin and MDMA.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced novel findings from ongoing studies presented by Dr. Matthias Liechti at the INSIGHT Conference in Berlin. The research indicates that a 100 mcg dose of LSD produces perceptual effects equivalent to a 20 mg dose of psilocybin, marking the first clinical evidence of their equivalence. Furthermore, psilocybin was deemed safe alongside SSRIs, with escitalopram reducing anxiety without affecting the psychedelic experience. CEO Robert Barrow highlighted the significance of understanding these substances for optimizing treatment programs.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has announced the participation of CEO Robert Barrow in several upcoming investor conferences. These include the Advances in Mental Health Virtual Conference on Sept. 22, 2021, CIBC's 20th Annual Eastern Institutional Conference on Sept. 23, and 2021 Cantor Virtual Global Healthcare Conference on Sept. 29. MindMed focuses on developing psychedelic-inspired therapies for addiction and mental illness, showcasing an innovative pipeline of treatments. Webcast replays will be available on MindMed's website for 30 days post-presentation.